FMI Foundation Medicine, Inc. (delisted)

This Schedule 13D/A (“ Amendment No. 4 ”), filed jointly by Roche Holding Ltd, a Swiss company (“ Parent ”), Roche Finance Ltd, a Swiss company and a wholly owned subsidiary of Parent (“ Finance ”), and Roche Holdings, Inc., a Delaware corporation and a wholly owned subsidiary of Finance (“ Holdings ” and, together with Parent and Finance, the “ Roche Entities ”) amends and supplements the Schedule 13D filed on January 11, 2015 (the “ Schedule 13D ”), as amended by Amendment No. 1 to the Schedule 13D filed on April 9, 2015, Amendment No. 2 to the Schedule 13D filed on April 14, 2015 and Amendment No. 3 to the Schedule 13D filed on June 19, 2018, with respect to the common stock, $0.0001 par value per share (the “ Shares ”), of Foundation Medicine, Inc., a Delaware corporation (the “ Company ”).

Item 4. Purpose of Transaction

Item 4 is hereby amended by adding the following:

On July 2, 2018, 062018 Merger Subsidiary, Inc., a Delaware corporation and wholly owned direct subsidiary of Holdings (“ Purchaser ”), commenced a tender offer (the “ Offer ”) to purchase all of the outstanding Shares at a price of $137.00 per Share net to the seller in cash, without interest and less any required withholding taxes, upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger dated June 18, 2018, between the Company, Holdings and Purchaser (the “ Merger Agreement ”). Purchaser’s obligation to accept for payment the Shares tendered in the Offer was conditioned upon, among other things, there being validly tendered and received and not withdrawn, prior to the expiration of the Offer, a number of Shares that represented at least a majority of the Shares then outstanding not already owned by the Roche Entities, on a fully diluted basis as of the date and time of the first acceptance for payment of Shares validly tendered and not withdrawn pursuant to the terms and conditions of the Offer (such condition, the “ Minimum Condition ”).

The Offer and withdrawal rights expired at 12:00 midnight, New York City time, at the end of the day on Monday, July 30, 2018 (the “ Expiration Date ”). The Depositary for the Offer has indicated that a total of 12,535,376 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 77.3% of the outstanding Shares (excluding Shares already owned by the Roche Entities). In addition, Notices of Guaranteed Delivery have been delivered for 1,342,573 Shares, representing approximately 8.3% of the outstanding Shares (excluding Shares already owned by the Roche Entities). The number of Shares tendered (excluding Shares presented pursuant to Notices of Guaranteed Delivery for which certificates were not yet delivered) satisfies the Minimum Condition, and all Shares that were validly tendered and not validly withdrawn pursuant to the Offer have been accepted for payment by Purchaser.

On July 31, 2018, Holdings completed its acquisition of the Company pursuant to the terms of the Merger Agreement. On such date, Purchaser merged with and into the Company in accordance with Section 251(h) of the DGCL, with the Company surviving as a wholly owned subsidiary of Holdings. Pursuant to the Merger Agreement, at the Effective Time, each Share issued and outstanding immediately prior to the Effective Time was converted into the right to receive $137.00 per Share in cash, without interest but subject to any required withholding of taxes (which is the same amount per Share paid in the Offer) other than (i) treasury Shares held by the Company and any Shares owned by Parent or any direct or indirect wholly owned subsidiary of Parent or the Company, and (ii) Shares held by any person who was entitled to and has properly demanded statutory appraisal of his or her Shares. Instructions outlining the steps to be taken to obtain the Merger Consideration will be mailed to the Company stockholders who did not tender their Shares in the Offer.

Promptly following consummation of the Merger, Holdings intends to cause all Shares to be delisted from NASDAQ and deregistered under the Exchange Act.

Item 5. Interest in Securities of the Company

Item 5 is hereby amended and restated to read as follows:

The beneficial ownership percentages described in this Schedule 13D are based on 101.1266 Shares outstanding as of July 31, 2018, based on information provided by the Company.

Finance and Parent may each be deemed for purposes of Rule 13d-3 promulgated under the Exchange Act to beneficially own 101.1266 Shares (calculated as the sum of (i) 100 Shares directly held by Holdings and (ii) 1.1266

Shares directly held by Finance, representing in the aggregate approximately 100% of the outstanding Shares as of July 31, 2018.

Holdings may be deemed for purposes of Rule 13d-3 promulgated under the Exchange Act to beneficially own 100 Shares, representing approximately 98.9% of the outstanding Shares as of July 31, 2018.

Except as set forth herein, no Reporting Person or, to the best knowledge of the Reporting Persons, any of the persons set forth on Schedules A to C hereto beneficially own any Shares.

(c)       Inapplicable.

(d)       Inapplicable.

(e)       Inapplicable.

SIGNATURE

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

July 31, 2018

Foundation Medicine, Inc. (NASDAQ:FMI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Foundation Medicine, Inc. (NASDAQ:FMI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024